BioAge Labs Reports Positive Phase 1 Data for Brain-Penetrant NLRP3 Inhibitor BGE-102
核心洞察
BioAge Labs (搜索) announced positive interim Phase 1 data for BGE-102, a novel oral NLRP3 (搜索) inhibitor that achieved 90-98% suppression of IL-1β (搜索) and demonstrated strong brain penetration at doses of 60 mg and higher.
The drug was well-tolerated across all tested doses and showed dose proportionality with a pharmacokinetic profile supporting once-daily oral dosing in healthy volunteers.
The company is expanding the Phase 1 trial to include obese participants with elevated hsCRP (搜索), with data expected in the first half of 2026, followed by a Phase 2a proof-of-concept study.
BioAge Labs (搜索) has reported encouraging interim Phase 1 data for BGE-102, a structurally novel NLRP3 (搜索) inhibitor that demonstrated strong target engagement and achieved a key differentiator in the competitive NLRP3 space: high brain penetration. The oral, once-daily drug showed 90-98% suppression of IL-1β (搜索), a cytokine directly downstream of NLRP3, while maintaining a favorable safety profile across all tested doses.
Strong Target Engagement and Safety Profile
In the ongoing Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial, BGE-102 was well-tolerated across all dose levels evaluated to date, including SAD cohorts at 10, 30, 60, and 120 mg, and MAD cohorts at 60 and 120 mg. Adverse events were infrequent and mild to moderate in severity, with all events resolving without intervention.
The drug demonstrated clear dose proportionality across all tested doses, with BGE-102 treatment achieving 90% suppression of IL-1β (搜索) at the 60 mg dose and 98% suppression at the 120 mg dose in an ex vivo whole blood stimulation assay prior to dosing on Day 14. In MAD cohorts, treatment with BGE-102 at 60 mg and higher achieved plasma concentrations exceeding IC90 for 24 hours.
Brain Penetration Sets BGE-102 Apart
A critical finding that distinguishes BGE-102 from other NLRP3 (搜索) inhibitors in development is its ability to penetrate the central nervous system. In MAD cohorts, BGE-102 doses of 60 mg and higher resulted in cerebrospinal fluid concentrations exceeding the IC90 after 14 days of treatment.
"The clear evidence of high brain penetration is especially important, as it supports BGE-102's potential to comprehensively target NLRP3 (搜索)-driven inflammation in both the central nervous system and peripheral tissues," said Kristen Fortney, PhD, CEO and co-founder of BioAge.
This dual action capability addresses a significant unmet need, as NLRP3 (搜索) is a key driver of age-related inflammation implicated in cardiovascular disease (搜索), neurodegenerative conditions (搜索), and metabolic disorders (搜索).
Expansion into Obesity Population
Based on the positive interim data, BioAge has expanded Part 2 of the Phase 1 study to evaluate two dose levels in obese participants with elevated high-sensitivity C-reactive protein (hsCRP (搜索)). The rationale for this expansion stems from the drug's potent IL-1β (搜索) suppression, as IL-1β is a key upstream regulator of CRP (搜索) production.
"Recent clinical experience has shown that NLRP3 (搜索) inhibitors can achieve substantial reductions in inflammatory biomarkers such as hsCRP (搜索) within the first week of treatment," said Paul Rubin, MD, Chief Medical Officer of BioAge. "Because IL-1β (搜索) is a key upstream regulator of CRP (搜索) production, the potent and sustained IL-1β suppression we observed with BGE-102 has the potential to translate directly into meaningful effects on hsCRP."
Clinical Development Timeline
The MAD portion in obese participants is ongoing, with data anticipated in the first half of 2026. BioAge plans to initiate a Phase 2a proof-of-concept study in patients with obesity (搜索) and cardiovascular risk factors in the first half of 2026.
The planned Phase 2a trial will enroll approximately 100 patients randomized 1:1 to placebo or BGE-102 monotherapy for 12 weeks. The anticipated primary endpoint is percent change in hsCRP (搜索), with the trial also assessing a range of inflammatory and metabolic biomarkers and including MRI imaging. Phase 2a data readout is expected in the second half of 2026.
Targeting a Validated Pathway
BGE-102 represents a structurally novel class of NLRP3 (搜索) inhibitors developed by BioAge with a unique mechanism and binding site. NLRP3 inhibition has emerged as a promising strategy for reducing levels of inflammatory biomarkers associated with cardiovascular risk, with recent clinical experience from other companies in the space demonstrating substantial reductions in inflammatory markers.
The ongoing Phase 1 study is a randomized, double-blind, placebo-controlled trial that initially evaluated SAD at four dose levels, followed by MAD administered once daily for 14 days in healthy volunteers. Pharmacodynamic effects were evaluated using an ex vivo whole blood stimulation assay that measures BGE-102's ability to inhibit production of IL-1β (搜索).